Savara Inc. (SVRA)
$4.26
-0.95 (-18.23%)Delayed quote.
Price history
Daily close- Start
- $5.21
- Latest close
- $4.26
- Period change
- -18.23%
- Period low
- $4.22
- Period high
- $6.94
Key metrics
- Market cap
- $939.86M
- Volume
- 17.08M
- Average volume
- 2.48M
- 52-week range
- $4.00 – $7.01
- Beta
- 0.25
- Last dividend
- —
- EPS (TTM)
- -$0.61
- P/E ratio
- -11.38
- Revenue (TTM)
- $0
- Net income (TTM)
- -$152.74M
- Total assets
- $155.93M
- Total debt
- $31.57M
- Cash and equivalents
- $29.81M
Key financials (trailing twelve months).
Company profile
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- CEO
- Matthew Pauls
- Employees
- 70
- Headquarters
- Yardley, PA, US
- IPO date
- 2017-04-28
- Website
- https://www.savarapharma.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | -$245.0K | -$78.03M | -$44.26M |
| Operating income | -$123.55M | -$103.20M | -$60.01M |
| EBITDA | -$118.75M | -$102.27M | -$59.13M |
| Net income | -$118.84M | -$95.88M | -$54.70M |
| Diluted EPS | -$0.53 | -$0.48 | -$0.33 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $33.18M | $15.13M | $26.59M |
| Total assets | $253.44M | $212.88M | $177.56M |
| Total liabilities | $50.30M | $41.43M | $37.19M |
| Total debt | $29.91M | $26.73M | $26.49M |
| Shareholders’ equity | $203.13M | $171.45M | $140.37M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$101.04M | -$89.09M | -$51.06M |
| Capital expenditure | -$22.0K | -$25.0K | -$296.0K |
| Free cash flow | -$101.06M | -$89.11M | -$51.36M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | -$66.0K | -$40.0K | -$20.59M | -$385.0K |
| Operating income | -$43.54M | -$40.97M | -$38.99M | -$33.43M | -$30.25M | -$31.44M |
| EBITDA | -$42.93M | -$40.13M | -$37.22M | -$32.20M | -$29.49M | -$30.37M |
| Net income | -$42.99M | -$40.23M | -$37.28M | -$32.24M | -$29.56M | -$30.40M |
| Diluted EPS | -$0.17 | -$0.16 | -$0.15 | -$0.13 | -$0.14 | -$0.14 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $29.81M | $41.80M | $38.79M | $33.18M | $16.28M | $17.44M |
| Total assets | $155.93M | $192.14M | $221.65M | $253.44M | $140.92M | $163.76M |
| Total liabilities | $48.08M | $48.48M | $45.61M | $50.30M | $46.54M | $43.28M |
| Total debt | $31.57M | $30.11M | $30.11M | $29.91M | $29.83M | $29.74M |
| Shareholders’ equity | $107.85M | $143.66M | $176.04M | $203.13M | $94.39M | $120.48M |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$42.46M | -$29.75M | -$33.05M | -$25.06M | -$22.53M | -$26.26M |
| Capital expenditure | -$353.0K | -$222.0K | -$54.0K | -$2.0K | -$2.0K | -$15.0K |
| Free cash flow | -$42.82M | -$29.97M | -$33.10M | -$25.06M | -$22.53M | -$26.28M |